Winning also, Tutogen Medical ( TTG) was up 75 cents, or 8.6%, to $9.47. Roth Capital upgraded the company from hold to buy Thursday morning. In other analyst action: Friedman Billings changed its price target for Valeant Pharmaceuticals ( VRX) from $26 to $22. And Merriman Curhan Ford downgraded Coley Pharmaceuticals ( COLY), whose developmental program suffered Pfizer's ( PFE) axe Wednesday, from buy to neutral. Valeant closed down 4 cents to $16.95, and Coley Pharmaceutical closed up 16 cents, or 4.6%, to $3.62.
Stocks soar as the gross domestic product rises at an annualized rate of 3.5% in the third quarter and continuing jobless claims fall. Gregg Greenberg recaps the action in The Real Story video (above).